Therapeutic Temperature Management in Pediatric Patients After Cardiac Arrest

Introduction to Pediatric TTM Guidelines

The American Heart Association recommends targeted normothermia, with a temperature range of 36.0°C to 37.5°C, for comatose pediatric patients after return of spontaneous circulation (ROSC), based on evidence from the 2019 Pediatric Advanced Life Support guidelines 1, 2, 3.

Targeted normothermia (36.0°C-37.5°C) is recommended over hypothermia (32°C-34°C) in comatose children following resuscitation from both out-of-hospital and in-hospital cardiac arrest, regardless of initial rhythm (shockable or non-shockable), with a Grade 2 recommendation from the French expert panel 2, 3.

The THAPCA-OH trial, which enrolled 295 pediatric patients, compared TTM at 33°C (32°C-34°C) versus 36.8°C (36°C-37.5°C) for 120 hours, and found no difference in 28-day mortality (57% TTM vs 67% control, p=0.08) or 12-month survival with favorable neurological outcome 1, 4.
The THAPCA-IH trial, which enrolled 329 patients, showed survival at 28 days and favorable neurological outcome at 1 year of 36% in TTM group versus 39% in control group (no significant difference), with temperature targets and duration similar to the THAPCA-OH trial 4.
Importantly, the "control" group in both trials maintained normothermia at 36.8°C (range 36°C-37.5°C), not uncontrolled temperature, highlighting the importance of targeted temperature management 1, 4.

In pediatric patients, the two large RCTs specifically tested hypothermia (32°C-34°C) against normothermia (36°C-37.5°C) and found no benefit to the lower temperature range, in contrast to adult guidelines which recommend a broader range of 32°C-36°C 1, 4.
Hypothermia in pediatric patients was associated with increased complications, including hypokalemia, thrombocytopenia, and more frequent need for renal replacement therapy, emphasizing the need for careful temperature management 4.

The target temperature of 36.0°C-37.5°C should be maintained for at least 24 hours, with fever prevention continuing for 72 hours, based on current practice and evidence from pediatric trials 1, 4.
Active fever prevention (maintaining temperature ≤37.5°C) should continue for at least 72 hours in comatose patients after ROSC, as recommended by guidelines 8.
Continuous core temperature monitoring is essential using esophageal, bladder, or pulmonary artery catheters, as axillary and oral measurements are inadequate for accurate temperature management 8.

Approximately 38-56% of pediatric cardiac arrest patients present with temperatures requiring active warming to reach normothermia, not cooling, highlighting the importance of individualized temperature management 1.
Prehospital cooling with rapid infusion of large volumes of cold intravenous fluid is not recommended and may cause harm, emphasizing the need for careful prehospital care 2, 9.